Core Viewpoint - The company is undergoing a change in control and asset acquisition, aiming for vertical integration of its supply chain through the acquisition of 95.5% of Beijing Jinkangpu's shares [1][2]. Group 1: Control Change and Management - The company plans to resume trading on December 24, 2025, and will initiate a control change and a comprehensive transaction plan [2]. - The original controlling shareholder intends to transfer 8.09% of shares and relinquish voting rights for 25.5% of shares, with Guangzhou Defu Nutrition Investment Partnership becoming the new controlling shareholder [2]. - As of February 10, 2026, the share transfer agreement and asset audit are progressing as planned, with the company committing to disclose updates every 30 days [2]. Group 2: Project Advancement - The acquisition is aimed at downstream vertical integration, focusing on synergy in technology, market, and raw materials [3]. - Beijing Jinkangpu possesses advantages in formula development and customer networks, which may enhance the company's application solution capabilities and customer loyalty post-acquisition [3]. - The effectiveness of the integration and the pace of business expansion will be key areas for long-term observation [3]. Group 3: Strategic Development - The company will continue to focus on high-quality market targets around its core business of natural health ingredients, considering both horizontal and vertical integration opportunities [4]. - The resources from Defu Capital may facilitate the company's transformation from a raw material supplier to a platform enterprise, potentially leading to governance optimization and resource integration [4]. Group 4: Capacity Expansion - The company has completed global capacity layout, but the new factories have a short operational history, resulting in low current capacity utilization [5]. - Future capacity release will depend on sales growth of core products, expansion into new categories, and the rollout of synthetic biology technology products [5].

另外，莱茵生物经过二十余年的深耕积淀，所形成的综合优势及行业地位，相信也是德福资本综合考量 的关键因素。一是产业布局完善、体系健全，公司拥有充足的产能储备、领先的生产技术、完善的QA 及QC质量管控体系、规范的治理结构，以及覆盖全球的销售网络，企业发展底盘坚实牢靠；二是公司 具备系统的选品、拓品与产品孵化能力， 这种能力依托于公司完整的研发、开发、产业化全链条布局，能够实现产品从概念到落地的高效转化； 三是具备业务持续升级的内驱力与技术迭代能力，公司始终保持敏锐的技术前瞻意识，近年来主动布局 合成生物、配方应用等前沿领域，并成功实现了技术的迭代升级，同时紧跟行业发展趋势，积极开拓动 物饲料、宠物营养等多元应用场景，体现了公司较好的发展活力与成长潜力。此次德福资本选择与莱茵 生物合作，既是对公司业务发展的高度认可，也彰显了对公司未来前景的坚定信心。 答：首先在战略层面，德福资本与莱茵生物都高度看好天然健康成分这一细分赛道，且德福资本对莱茵 生物的发展战略予以高度认可。双方在战略层面高度契合、理念一致，这是此次合作达成的基础前提， 也是核心驱动力之一。 格隆汇2月11日丨莱茵生物(002166.SZ)在投资者关系 ...

另外，莱茵生物经过二十余年的深耕积淀，所形成的综合优势及行业地位，相信也是德福资本综合考量 的关键因素。一是产业布局完善、体系健全，公司拥有充足的产能储备、领先的生产技术、完善的QA 及QC质量管控体系、规范的治理结构，以及覆盖全球的销售网络，企业发展底盘坚实牢靠；二是公司 具备系统的选品、拓品与产品孵化能力， 这种能力依托于公司完整的研发、开发、产业化全链条布局，能够实现产品从概念到落地的高效转化； 三是具备业务持续升级的内驱力与技术迭代能力，公司始终保持敏锐的技术前瞻意识，近年来主动布局 合成生物、配方应用等前沿领域，并成功实现了技术的迭代升级，同时紧跟行业发展趋势，积极开拓动 物饲料、宠物营养等多元应用场景，体现了公司较好的发展活力与成长潜力。此次德福资本选择与莱茵 生物合作，既是对公司业务发展的高度认可，也彰显了对公司未来前景的坚定信心。 答：首先在战略层面，德福资本与莱茵生物都高度看好天然健康成分这一细分赛道，且德福资本对莱茵 生物的发展战略予以高度认可。双方在战略层面高度契合、理念一致，这是此次合作达成的基础前提， 也是核心驱动力之一。 格隆汇2月11日丨莱茵生物(002166.SZ)在投资者关系 ...